Tofersen demonstrates positive results in Phase I/II trial for amyotrophic lateral sclerosis

Written by Sharon Salt, Senior Editor

Biogen (MA, USA) has announced positive results from a Phase I/II study of tofersen – an antisense oligonucleotide – for the potential treatment of SOD1 amyotrophic lateral sclerosis (ALS). These results have been published in The New England Journal of Medicine. The Phase I/II study of tofersen was a randomized, placebo-controlled, single- and multiple-ascending dose study that evaluated the safety, pharmacokinetics, pharmacodynamics and exploratory efficacy endpoints in individuals living with SOD1-ALS. In the multiple-ascending dose part of the study, participants with SOD1-ALS were randomized to receive either tofersen (20 mg, 40 mg, 60 mg or 100 mg) or placebo for...

To view this content, please register now for access

It's completely free